

ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/  
Form 8-K  
August 07, 2006

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### **FORM 8-K**

#### CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 2, 2006

### **Arrhythmia Research Technology, Inc.**

*(Exact name of issuer as specified in its charter)*

Delaware

1-9731

72-0925679

*(State or other jurisdiction of Incorporation  
or organization)*

*(Commission File Number)*

*(I.R.S. Employer Identification Number)*

25 Sawyer Passway

Fitchburg, MA 01420

*(Address of principal executive offices and zip code)*

Edgar Filing: ARRHYTHMIA RESEARCH TECHNOLOGY INC /DE/ - Form 8-K

**(978) 345-5000**

*(Registrant's telephone number, including area code)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 2.02. Results of Operations and Financial Condition**

On August 2, 2006, The Company issued a press release announcing its financial results for the 2nd quarter ended June 30, 2006. The press release is attached as Exhibit 99.1 to this report.

The information set forth in the above Item 2.02 and the attached Exhibit 99.1 is furnished to, but shall not be deemed filed with the Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise incorporated by reference into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such a filing.

**Item 9.01. Financial Statements and Exhibits**

(c). Exhibits

| <u>Exhibit Number</u> | <u>Description</u>  |
|-----------------------|---|
| 99.1                  | <u>Press Release dated August 2, 2006 announcing its financial results for the 2nd quarter ended June 30, 2006.</u> |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fitchburg, Commonwealth of Massachusetts, on the 7th day of August 2006.

ARRHYTHMIA RESEARCH TECHNOLOGY,  
INC.

By: /s/ David A. Garrison  
David A. Garrison  
Executive Vice President and  
Chief Financial Officer

**Exhibit Index**

| <u>Exhibit Number</u> | <u>Description</u>  |
|-----------------------|---|
| <u>99.1</u>           | <u>Press Release dated August 2, 2006 announcing its financial results for the 2nd quarter ended June 30, 2006.</u> |